Printer Friendly

Catalent, Adial Enter Clinical Supply Partnership.

A dial Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, has formed a partnership with Catalent Pharma Solutions to advance clinical activities related to AD04, Adial's genetically targeted, lead investigational new drug product for the treatment of alcohol use disorder (AUD). The partnership will allow the commencement of Adial's initial Phase III trial, with Catalent providing packaging and distribution services.

Based on the clinical experience to date and publicly available databases, Adial believes the genetic prevalence of genotypepositive AUD patients in the U.S. is about 33%, or about 11 million people, and that the prevalence in Scandinavia and in certain areas of Eastern Europe may be even higher, with possibly more than 50% being genetically positive for treatment with AD04. Adial plans to begin the Phase III trial of AD04 in Scandinavia and Eastern Europe during 1H19.

Catalent will be responsible for packaging and distributing AD04 to clinical sites. With additional facilities in the Asia/ Pacific region and in Latin America, Catalent provides capabilities that should also be important in the future development of AD04, and for the eventual commercial launch of the product, once approved.

"We look forward to continuing our long-term relationship with Catalent, which will provide critical distribution and logistics support for AD04 in our upcoming Phase m trial," said Mr. Stilley. "With facilities and personnel servicing Scandinavia and Eastern Europe, Catalent is an ideal partner; we believe that its packaging and logistics expertise and GMP facilities are well equipped to support our planned clinical sites. In addition, Catalent brings broad capabilities in the U.S. and globally, which should be important as we seek to expand our clinical development activities and initiate commercialization promptly upon approval."

Paul Hegwood, president, clinical supply services, Catalent, said, "Catalent is pleased to enter this partnership and we look forward to working with Adial as it drives to bring this new drug product to patients for the treatment of alcohol use disorder."

COPYRIGHT 2019 Rodman Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:INDUSTRY NEWS
Publication:Contract Pharma
Date:Mar 1, 2019
Words:327
Previous Article:INTERPHEX 2019 Preview: Explore solutions for cost effective development and manufacture of quality products.
Next Article:Boehringer, IBM Explore Blockchain Technology in Clinical Trials.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |